AbbVie Inc
ABBV
Company Profile
Business description
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Contact
1 North Waukegan Road
North ChicagoIL60064-6400
USAT: +1 847 932-7900
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
50,000
AbbVie Inc News & Analysis
markets
4 charts on the US rotation out of growth and tech stocks
Value stocks among financials, healthcare and consumer defensive sectors are supporting the market.
markets
Markets brief: US value stocks have suffered in 2023 but are showing signs of recovery
These stocks have led the latest gains for the value side of the market.
funds
Under the hood of Australia’s largest sustainable ETF
Despite strong performance and strict exclusion criteria, BetaShares' ETHI includes firms accused of tax evasion.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.10 | 48.60 | 0.57% |
| CAC 40 | 7,355.37 | 72.68 | 1.00% |
| DAX 40 | 19,984.32 | 135.55 | 0.68% |
| Dow JONES (US) | 42,992.21 | 333.59 | -0.77% |
| FTSE 100 | 8,149.78 | 12.79 | 0.16% |
| HKSE | 20,090.46 | 7.83 | -0.04% |
| NASDAQ | 19,722.03 | 298.33 | -1.49% |
| Nikkei 225 | 40,281.16 | 713.10 | 1.80% |
| NZX 50 Index | 13,205.10 | 130.36 | 1.00% |
| S&P 500 | 5,970.84 | 66.75 | -1.11% |
| S&P/ASX 200 | 8,261.80 | 40.90 | 0.50% |
| SSE Composite Index | 3,400.14 | 2.07 | 0.06% |